Abstract
Poxviruses are among prime candidates for generation of recombinant virus vaccines against infectious diseases and cancer. Poxvirus-based experimental vaccines have already proven to be efficient with regard to antigen delivery and the induction of antigen-specific immune responses in several animal models and first clinical trials (1–7). Live vector vaccines are designed to mimic microbial infections allowing for de novo synthesis of vaccine antigens that appear particularly suitable for presentation via MHC-I molecules. Vaccination with these live vaccines may elicit appropriate “danger” signals to the immune system, resulting in preferential recognition and presentation of recombinant (vaccine) antigens. Additional features of poxvirus vectors include the ability to accommodate large amounts of foreign DNA, high stability, and reasonable cost of manufacturing. However, vaccinia virus—the prototype live viral vaccine—can replicate in humans, and its imperfect safety record as a smallpox vaccine was a concern for its use as a vector in clinical applications. Therefore, most of the currently evaluated recombinant vaccines are based on vectors derived from highly attenuated vaccinia viruses such as modified vaccinia virus Ankara (MVA) (8), NYVAC (9) or avipoxviruses (10,11). These viruses all share the property of replication deficiency in mammalian cells that may have contributed to the already established clinical safety of these vectors (12–14). Importantly, even high dose inoculation of MVA was shown to be safe in immune-suppressed macaques, suggesting the safety of recombinant MVA vaccines in potentially immunocompromised individuals (15).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zavala, F., Rodrigues, M., Rodriguez, D., Rodriquez J. R., Nussenzweig, R. S., and Esteban, M. (2001) A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 280, 155–159.
Moss, B. (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc. Natl. Acad. Sci. USA 93, 11,341–11,348.
Rosenberg, S. A. (1997) Cancer vaccines based on the identification of the genes encoding cancer regression antigens. Immunol. Today 18, 175–182.
Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R., and Moss, B. (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032–1040.
Hirsch, V. M., Fuerst, T. R., Sutter, G., Carroll, M. W., Yang, L. C., Goldstein, S., et al. (1996) Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70, 3741–3752.
Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397–402.
Amara, R. R., Villinger, F., Altman, J. D., Lydy, O’Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., et al. (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.
Sutter, G. and Moss, B. (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10,847–10,851.
Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J-C., Cox, W. I., et al. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217–232.
Taylor, J., Weinberg, R., Languet, B., et al. (1988) Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6, 497–503.
Taylor, J., Trimarchi, C., Weinberg, R., Languet, B., Guillemin, F., Desmettre, P., et al. (1991) Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9, 190–193.
Meyer, H., Sutter, G., and Mayr, A. (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72, 1031–1038.
Drexler, I., Heller, K., Wahren, B., Erfle, V., and Sutter, G. (1998) Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79, 347–352.
Carroll, M. W. and Moss, B. (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198–211.
Stittelaar, K. J., Kuiken, T., de Swart, R. L., van Amerongen, G., Vos, H. W., Niesters, H. G. M., et al. (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19, 3700–3709.
Ramirez, J. C., Gherardi, M. M., Rodriguez, D., and Esteban, M. (2000) Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74, 7651–7655.
Kaerber, G. (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162, 480.
Staib, C., Drexler, I., Ohlmann, M., Wintersperger, S., Erfle, V., and Sutter, G. (2000) Transient host range selection for genetic engineering of modified vaccinia virus Ankara. BioTechniques 6, 1137–1142, 1144–1146, 1148.
Sutter, G., Ohlmann, M., and Erfle, V. (1995). Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett. 371, 9–12.
Drexler, I., Antunes, E., Schmitz, M., Wolfel, T., Huber, C., Erfle, V., et al. (1999) Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase-and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 59, 4955–4963.
Wyatt, L. S., Shors, S. T., Murphy, B. R., and Moss, B. (1996) Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14, 1451–1458.
Carroll, M. and Moss, B. (1995) E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. BioTechniques 19, 352–355.
Staib, C., Löwell, M., Erfle, V., and Sutter, G. (2003) Improved host range selection for recombinant modified vaccinia virus Ankara. BioTechniques 34, (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Staib, C., Sutter, G. (2003). Live Viral Vectors. In: Robinson, A., Hudson, M.J., Cranage, M.P. (eds) Vaccine Protocols. Methods in Molecular Medicine™, vol 87. Humana Press. https://doi.org/10.1385/1-59259-399-2:51
Download citation
DOI: https://doi.org/10.1385/1-59259-399-2:51
Publisher Name: Humana Press
Print ISBN: 978-1-58829-140-0
Online ISBN: 978-1-59259-399-6
eBook Packages: Springer Protocols